Nkarta, Inc. expected to post a loss of 38 cents a share - Earnings Preview
Nkarta, Inc. <NKTX.OQ> expected to post a loss of 38 cents a share - Earnings Preview
Nkarta, Inc. NKTX.OQ NKTX.O is expected to show no change in quarterly revenue when it reports results on August 10 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Nkarta, Inc. is for a loss of 38 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Nkarta, Inc. is $11.00, about 380.3% above its last closing price of $2.29
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.36 | -0.37 | -0.37 | Met | 0.7 |
Dec. 31 2026 | -0.32 | -0.37 | Missed | -16.4 | |
Sep. 30 2025 | -0.30 | -0.31 | -0.29 | Beat | 7.4 |
Jun. 30 2025 | -0.47 | -0.35 | -0.31 | Beat | 12.7 |
Mar. 31 2025 | -0.43 | -0.44 | -0.43 | Beat | 2.3 |
Dec. 31 2024 | -0.46 | -0.41 | -0.35 | Beat | 15.2 |
Sep. 30 2024 | -0.36 | -0.36 | -0.39 | Missed | -6.8 |
Jun. 30 2024 | -0.40 | -0.45 | -0.34 | Beat | 24.4 |
This summary was machine generated August 7 at 14:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Nkarta
See all newsNkarta, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Brief: Nkarta Q2 EPS USD -0.54
Nkarta, Inc. expected to post a loss of 38 cents a share - Earnings Preview
Biotech experts want FDA drug reviews based on science, not politics (updated)